

Special Issue

Safety and Autoimmune Response to SARS-CoV-2 Vaccination

Message from the Guest Editor

Coronavirus disease 2019 (COVID-19) is a new global public health crisis affecting the entire world. Following the introduction and wide use of SARS-CoV-2 vaccination, different adverse effects and complications were reported. Although important post-marketing surveillance of vaccines is ongoing, SARS-CoV-2 vaccines are currently still considered highly effective and safe, even with neurological adverse events following immunization (AEFI). These transient symptoms include cerebral venous sinus thrombosis, demyelinating episodes, lymphadenopathy, nausea, cognitive decline, or local influences of swelling, erythema, pain, fever/chills, fatigue, headache, dizziness, muscle weakness, and myalgia/arthralgia. This Special Issue aims to publish high-quality reviews, regular research papers, communications, and case reports on the safety of the SARS-CoV-2 vaccine in the general population and in special groups, proposals of different schedules and their effects on vaccine safety, security of neurological adverse events following immunization, and other aspects that may be proposed. We look forward to receiving your contributions.

Guest Editor

Dr. Minghui Yang

Department of Surgery, Kaohsiung Medical University Hospital,
Kaohsiung Medical University, Kaohsiung 807, Taiwan

Deadline for manuscript submissions

closed (20 November 2023)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/122903

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).